Loading...
OTCM
CSUI
Market cap706kUSD
Jul 09, Last price  
0.01USD
1D
0.00%
1Q
13.64%
IPO
-98.95%
Name

Cannabis Suisse Corp

Chart & Performance

D1W1MN
No data to show
P/E
P/S
23.56
EPS
Div Yield, %
Shrs. gr., 5y
-1.86%
Rev. gr., 5y
31.85%
Revenues
30k
+200.00%
014,1926,5007,530242,73950,8507,77010,00030,000
Net income
-1m
L+259.73%
-1,732-26,672-16,421-22,728-389,228-471,238-218,625-351,547-1,264,629
CFO
-46k
L-72.17%
-8,328-32,221-6,400-11,860-288,828-130,606-32,089-163,960-45,637

Profile

Cannabis Suisse Corp. engages in the cultivation, production, and distribution of over-the-counter products, recreational tobacco products, and medical CBD oils. The company sells its products through Swiss4Life, a retail brand for online selling, as well as a network of retailers. It provides health-related supplements, and face masks and disinfectants, as well as retails cigarettes. The company was formerly known as Geant Corp. and changed its name to Cannabis Suisse Corp. in February 2019. Cannabis Suisse Corp. was incorporated in 2016 and is based in Bell Gardens, California.
IPO date
May 24, 2018
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑05
Income
Revenues
30
200.00%
10
28.70%
Cost of revenue
283
348
Unusual Expense (Income)
NOPBT
(253)
(338)
NOPBT Margin
Operating Taxes
(164)
Tax Rate
NOPAT
(253)
(175)
Net income
(1,265)
259.73%
(352)
60.80%
Dividends
Dividend yield
Proceeds from repurchase of equity
20
BB yield
Debt
Debt current
260
135
Long-term debt
2,028
549
Deferred revenue
Other long-term liabilities
Net debt
2,259
891
Cash flow
Cash from operating activities
(46)
(164)
CAPEX
Cash from investing activities
Cash from financing activities
74
164
FCF
(1,052)
(212)
Balance
Cash
29
(207)
Long term investments
Excess cash
27
Stockholders' equity
(2,608)
(1,385)
Invested Capital
3,306
1,495
ROIC
ROCE
EV
Common stock shares outstanding
47,317
42,036
Price
Market cap
EV
EBITDA
(248)
(334)
EV/EBITDA
Interest
27
9
Interest/NOPBT